首页 | 本学科首页   官方微博 | 高级检索  
     

小细胞肺癌中MTA1蛋白的表达及其与化疗敏感性和预后的关系
引用本文:陈一天,徐益琛,陶累累,印洪林,余波,陈龙邦. 小细胞肺癌中MTA1蛋白的表达及其与化疗敏感性和预后的关系[J]. 临床肿瘤学杂志, 2014, 19(2): 102-106
作者姓名:陈一天  徐益琛  陶累累  印洪林  余波  陈龙邦
作者单位:1 210002 南京 第二军医大学南京临床医学院 南京军区南京总医院肿瘤内科2 210002 南京大学医学院临床学院3 210002 南京军区南京总医院病理科
基金项目:国家自然科学基金资助项目(81272734)
摘    要:目的 检测转移相关基因1(MTA1)蛋白在小细胞肺癌(SCLC)组织中的表达情况,探讨其在SCLC转移、预后和化疗敏感性预测中的作用。方法 采用免疫组织化学法检测52例无远处转移SCLC组织标本中MTA1的表达,根据免疫组化结果分为两类:低表达(≤6分)和高表达(>6分);分析MTA1表达水平与临床病理特征、EP方案(足叶乙甙100mg/m2静滴,d1~d5;顺铂60mg/m2静滴,d1,3周为1周期,共4~6个周期)化疗疗效及预后的关系。结果 52例SCLC组织中MTA1高表达率为71.2%(37/52),18例癌旁组织均为低表达(100.0%);MTA1表达在不同肿瘤直径、TNM分期、淋巴结转移与否和有无脉管侵犯之间的差异有统计学意义(P<0.05),而在性别、年龄、VALG分期及肿瘤部位之间的差异无统计学意义(P>0.05);MTA1高表达组的EP方案化疗敏感率低于MTA1低表达组(54.1% vs. 80.0%,P=0.020);MTA1低表达组的中位无进展生存期和总生存期均优于MTA1高表达组(20个月vs.8个月,33个月vs.18个月),差异有统计学意义(P<0.05)。结论 MTA1在SCLC组织中高表达,且与肿瘤转移、耐药及预后密切相关。

关 键 词:小细胞肺癌  转移  耐药  预后  转移相关基因1蛋白
收稿时间:2013-08-30
修稿时间:2013-10-22

Expression of MTA1 protein in small cell lung cancer and its correlation with chemotherapy sensitivity and prognosis
CHEN Yitian,XU Yichen,TAO Leilei,YIN Honglin,YU Bo,CHEN Longbang. Expression of MTA1 protein in small cell lung cancer and its correlation with chemotherapy sensitivity and prognosis[J]. Chinese Clinical Oncology, 2014, 19(2): 102-106
Authors:CHEN Yitian  XU Yichen  TAO Leilei  YIN Honglin  YU Bo  CHEN Longbang
Affiliation:Department of Medical Oncology, Nanjing Clinical College of the Second Military Medical University, Nanjing General Hospital of Nanjing Military Command, PLA, Nanjing 210002, China
Abstract:Objective To detect the expression of metastasis-associated-gene 1 (MTA1) protein in tissues of small cell lung cancer(SCLC) and explore the role of MTA1 in metastasis, prognosis and chemotherapy sensitivity of SCLC. Methods The expression of" MTA1 was detected in 52 non-distal metastatic SCLC tissues by immunohistochemical staining. The results were divided into low-level expression(~〈6) and high-level expression(〉6) according to the immunohistochemical staining counting method. The re- lationships between expression of MTA1 and clinicopathological characteristics, efficacy of EP regimen( etoposide 100mg/m2 iv, d1-d5 ; cisplatin 60mg/m2 iv d1 ; 3-week cycle for 4-6 cycles) and prognosis were investigated. Results Thirty-seven SCLC tissues were found of high-level MTA1 expression(71.2%) , while MTA1 was expressed at a low-level in all 18 adjacent tissues. There were significant correlations between the expression of MTA1 and tumor size, TNM stage, lymph node metastasis and vascular invasion(P〈0. 05). No significant correlation existed between the expression of MTA1 and gender, age, VALG stage and tumor sites (P〉0. 05). The low-level expression group was more sensitive to EP chemotherapy than the high-level expression group(80. 0% vs. 54. 1%, P= 0. 020). The me- dian progression-free survival and overall survival of the low-level expression group were superior to those of the high-level expression group(20 months vs. 8 months, 33 months vs. 18 months) with statistical significance (P〈0. 05). Conclusion MTA1 is highly ex- pressed in SCLC tissue, and is closely correlated with tumor metastasis, drug resistance and prognosis.
Keywords:Small cell lung cancer (SCLC)  Metastasis  Drug resistance  Prognosis  Metastasis-associated gene 1( MTA1 ) protein
本文献已被 维普 等数据库收录!
点击此处可从《临床肿瘤学杂志》浏览原始摘要信息
点击此处可从《临床肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号